Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/12/18 (What's New)

Summary

  • GS-1878 evaluated the efficacy and safety of switching virologically suppressed HIV-infected adult patients from a multitablet regimen containing a boosted PI to fixed-dose bictegravir/emtricitabine/tenofovir AF[Daar 2017]
    • In this ongoing study, the switch to bictegravir/emtricitabine/tenofovir AF was found to be noninferior to continuing a boosted PI–containing regimen and demonstrated no treatment-emergent resistance at 48 weeks

Action required

Keywords: Adherence, Cardiovascular Disease, Dyslipidemia, Fat Perturbations, Switch Strategies, Treatment Complications

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.